Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NRCIA: 14.03 (-0.18), VCYT: 8.24 (+0.07), ISIS: 59.49 (+1.88), CBST: 100.29 (-0.09), AKAO: 12.76 (-0.23), CLDN: 18.54 (+0.85), PDCE: 43.46 (-1.39), MTEX: 28.96 (unch), NRCIB: 35.90 (+0.30)
Veracyte Announces Positive Coverage Policy for Afirma® Gene Expression Classifier from Blue Shield of California
PR Newswire - Tue Dec 02, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced today that Blue Shield of California, one of the nation's largest Blue Cross Blue Shield (BCBS)-affiliated organizations, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC), effective immediately. Blue Shield of California's decision makes the Afirma GEC available to its approximately 3 million members and brings the total number of covered lives for Veracyte's test to more than 140 million. Additionally, the Hawaii Medical Services Association (HMSA) - also a BCBS-affiliated organization - published a draft policy indicating it intends to cover Veracyte's genomic test for its members beginning in February 2015.
VCYT: 8.24 (+0.07)
Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference
PR Newswire - Mon Nov 24, 6:39AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.
VCYT: 8.24 (+0.07)
Veracyte's (VCYT) CEO Bonnie Anderson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 11:45PM CST
VCYT: 8.24 (+0.07)
Veracyte misses Street 3Q forecasts
Automated Insights - Thu Nov 13, 4:48PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a third-quarter loss of $7.9 million.
VCYT: 8.24 (+0.07)
Veracyte misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:31PM CST
VCYT: 8.24 (+0.07)
Veracyte, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:05PM CST
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2014 and provided an update on business progress. For the third quarter of 2014, revenue was $9.8 million, an increase of 76%, compared to $5.6 million for the third quarter of 2013. Revenue for the nine months ended September 30, 2014 was $26.0 million, compared to $15.0 million for the same period in 2013, an increase of 73%.
VCYT: 8.24 (+0.07)
Veracyte Announces Appointment of John L. Bishop to Its Board of Directors Following the Resignation of Samuel D. Colella
PR Newswire - Wed Nov 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The Veracyte Board accepted his resignation at its November 11, 2014 meeting, during which it also approved the selection of veteran diagnostics executive John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board's Compensation Committee.
VCYT: 8.24 (+0.07)
Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Thu Nov 06, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014. Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
VCYT: 8.24 (+0.07)
Veracyte, Inc. Announces New Data Supporting Clinical Validity of Afirma® Gene Expression Classifier
PR Newswire - Wed Oct 29, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced new data from two studies supporting the use of the company's Afirma Gene Expression Classifier (GEC) to help reduce unnecessary surgeries among patients whose thyroid nodules are indeterminate for cancer following traditional cytopathology review of their fine needle aspiration (FNA) biopsies. The data are being presented at the 84th Annual Meeting of the American Thyroid Association in Coronado, Calif., October 29 - November 2.
VCYT: 8.24 (+0.07)
Veracyte Inc. to Host Investor Day on October 9, 2014
PR Newswire - Thu Oct 02, 6:30AM CDT
Veracyte Inc. (Nasdaq: VCYT) today announced that the company will host a live webcast in conjunction with its Investor Day on Thursday, October 9, 2014 at 12:00 p.m. ET in New York, NY.
VCYT: 8.24 (+0.07)
Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer
PR Newswire - Wed Sep 17, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the promotion of Christopher M. Hall to chief operating officer.
VCYT: 8.24 (+0.07)
Veracyte, Inc. to Acquire Allegro Diagnostics, Accelerating Entry Into Pulmonology Market
PR Newswire - Thu Sep 04, 3:30PM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced an agreement to acquire Allegro Diagnostics Corp. based in Maynard, Mass., for $21.0 million, comprised of $7.8 million in cash and $13.2 million in Veracyte common stock. Allegro is a privately held company focused on developing genomic tests to improve the preoperative diagnosis of lung cancer.
VCYT: 8.24 (+0.07)
Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014
PR Newswire - Tue Sep 02, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat format discussion at the Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at 3:25 p.m. ET in New York.
VCYT: 8.24 (+0.07), MS: 38.81 (-0.14)
Veracyte, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Wed Aug 13, 3:05PM CDT
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the second quarter ended June 30, 2014, and provided an update on business progress. For the second quarter of 2014, revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Revenue for the six months ended June 30, 2014 was $16.2 million, compared to $9.5 million for the same period in 2013, also an increase of 71%.
VCYT: 8.24 (+0.07)